Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Arcutis Biotherapeutics, Inc. (ARQT) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "Arcutis Announces Second Quarter 2023 Financial Results and Provides Business Update"
05/09/2023 8-K Quarterly results
Docs: "Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update"
11/08/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
02/22/2022 8-K Quarterly results
Docs: "Arcutis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update"
11/04/2021 8-K Quarterly results
Docs: "Arcutis Announces Third Quarter 2021 Financial Results and Provides Business Update"
08/05/2021 8-K Quarterly results
05/04/2021 8-K Quarterly results
02/16/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "Arcutis Announces Third Quarter 2020 Financial Results and Provides Business Update"
08/11/2020 8-K Quarterly results
05/13/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 12, 2020 ARCUTIS BIOTHERAPEUTICS, INC. Delaware 001-39186 81-2974255 2945 Townsgate Road, Suite 110 Westlake Village, CA 91361 Registrant's telephone number, including area code: 418-5006 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-c...",
"Arcutis Announces First Quarter 2020 Financial Results and Provides Business Update • Multiple important Phase 3 and Phase 2 data events anticipated during 2020/2021 • Arcutis currently expects no impact to its previously disclosed clinical timelines due to COVID-19"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy